Compound Trade Name Companies Method of Action FDA Trials Phase
iloperidone Zomaril Titan/Novartis D2/5-HT2 antagonist Phase III
DTA 201A Knoll (BASF) D3 antagonist Phase II
DU 127090 Solvay/Lundbeck D2/5-HT1a antagonist Phase II
ORG 5222 Organon (Akzo Nobel) D2/5-HT2 antagonist Phase II
Osanetant Sanofi-Synthelabo neurokinin-3 antagonist Phase II
MEM 3454 Memory Pharmaceuticals Corp. partial agonist of the nicotinic alpha-7 receptor Phase I

Schizophrenia Medications in Development – A Special Report (Dec 2004)




Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s